Member Info for kezzman

shukan and cash I hope you are on the money and I am proven wrong here

Is it the usual low free float shares in scarce supply and a buy out coming? what a rise

to 24p here for starters Should get some assistance from the momentum traders now At least we know they are doing something behind the scenes now and not just sitting on their backsides drawing a fat wage like most aim BOD

any news due?

I've written this off now, If by some miracle they do pull something out of the hat would be a nice bonus But its looking like another AIM scam I've got caught up in. The silence from SILF is deafening I'm in ONZ too which is suspended hope that comes good

cheers pal sounds like a few in early are gonna have nice xmas

cheers bud must be some investments for a 150% rise

here? apart from tiny free float news coming?

doh well spotted replace million with thousand I must be getting over excited lol

over 500 million shares traded already steady on us LTH aren't used to this volume might have to have a lie down 500 million shares a month is the norm here

yep me too looks like you are right the RNS is slowly filtering out and we have buyers climbing aboard again Big part of this investing malarky is patience, I was close to throwing towel in here in my darkest hour lol lets see how it is at close of play should see a bit more interest now wonder if Kevs in now

missing characters shreprophets

biased I know but has a target 49p http://www.*************.com/file_download/837/amyt.pdf

investment now equity finance needed to construct the mine something doesn't feel right here we will see

well that went down well with the market

mmmmmmmmmm

Joe Wiley, CEO, commented: "This €20m facility with the European Investment Bank is a significant milestone for Amryt and represents a material endorsement of our potential from a leading European investment body. We are delighted to have secured non-dilutive funding for the pivotal Phase 3 clinical trial of Episalvan, our lead asset. The facility also enables us to progress our acromegaly drug compound, AP 102, as well as consider other licensing opportunities as part of our ongoing strategy to acquire, develop and commercialise products for rare and orphan diseases. We remain very excited about the potential of Episalvan to treat Epidermolysis Bullosa, a rare and distressing hereditary skin disorder that affects about 500,000 patients worldwide. Currently, there is no available treatment for EB and we believe that Episalvan, a topical gel, has a compelling clinical profile. EB is one of the many rare diseases where sufferers currently have no treatment options - there are 7,000 known rare diseases but only circa 550 orphan drugs have been approved to date. Having now fully funded our Episalvan program, we will look for further opportunities to fill the incredibly high unmet need in the orphan drugs market." Andrew McDowell, European Investment Bank Vice President, commented: "Continued investment in innovation is crucial to improve lives and build on European strengths to develop world-leading pharmaceutical products. The European Investment Bank is pleased to support innovation and development of new treatment of painful skin disorders by Amryt Pharma. This represents the EIB's first-ever direct support for investment by an Irish pharma company and I am pleased to confirm the EIB's intention to increase support for private sector innovation in Ireland in the years ahead."

Amryt, the clinical-stage specialty pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that it has entered into a €20m facility agreement ("Facility") with the EIB on highly attractive terms for the Company. The Facility is significant because it provides non-dilutive funding that secures the Company's near and mid-term funding needs for its lead product, Episalvan. It also provides the funding required to progress the Company's orphan designated acromegaly drug compound, AP 102, through pre-clinical development and into the clinic. As previously announced, the Company has submitted its protocol for the pivotal phase 3 study for Episalvan, to demonstrate its efficacy and safety for the treatment of Epidermolysis Bullosa ("EB"). The Phase 3 clinical trial in EB is expected to be initiated in Q1 of 2017 with top-line data anticipated to be available in mid-2018 and commercial launch expected in 2019. EB is a rare and inherited skin disorder that causes the skin to become very fragile and for which there is currently no available treatment. The Company recently secured a US patent for the use of Episalvan in the treatment of EB, having previously obtained a patent in Europe for the treatment of all partial thickness wounds, including those from EB. The EB market in the US and Europe is estimated to be worth c. US$1.5 billion per annum. Key terms of the Facility The Facility has a five-year term from drawdown and the associated repayment schedule is expected to present a minimal cash burden to the Company during the term, ahead of repayment. The Facility is split into three tranches, with €10 million available immediately and two further tranches of €5 million available upon the achievement of certain milestones in relation to Episalvan. The Facility has an interest rate of 3% over the Euro Interbank Offered Rate to be paid periodically, with a further 10% accruing and payable in a bullet together with the outstanding principal amount on expiry of the Facility. Joe Wiley, CEO, commented: "This €20m facility with the European Investment Bank is a significant milestone for Amryt and represents a material endorsement of our potential from a leading European investment body. We are delighted to have secured non-dilutive funding for the pivotal Phase 3 clinical trial of Episalvan, our lead asset. The facility also enables us to progress our acromegaly drug compound, AP 102, as well as consider other licensing opportunities as part of our ongoing strategy to acquire, develop and commercialise products for rare and orphan diseases. We remain very excited about the potential of Episalvan to treat Epidermolysis Bullosa, a rare and distressing hereditary skin disorder that affects about 500,000 patients worldwide. Currently, there is no available treatment for EB and we believe that Episalvan, a topical gel, has a c

?

Dear Shareholders In line with the new strategy of Highway Capital, of which the general outline was presented through the Chairman's statement in the latest Annual Report, the first half of 2016 was marked with intense efforts aimed at strengthening of the business position of the Company. The Company's directors have been seeking to identify profitable potential transactions on the one hand, and to seek reliable sources of financing on the other. A number of possible deals have been considered in respect of both of these aspects and we continue to investigate further opportunities. The decision was taken in May 2016 to provide finance of approximately £89,000 by way of a loan to Mylux, a Cypriot SPV. Mylux utilised the proceeds of the loan to acquire a 48% interest in a new payment services company in Poland known as Multipay. A further loan of £120,000 was advanced to Mylux in June 2016 in order to acquire a minority investment in a medical technology company. Although neither loan constituted an acquisition for the purposes of the Listing Rules under which the Company operates, the UK Listing Authority informed the directors in September 2016 that they considered that making the loans fundamentally changed the strategic direction of the business away from its stated aim to find an acquisition that would enhance shareholder value. As a result, the Company's shares were suspended from trading on 22 September pending the completion of the "reverse" procedure required to resume trading. Rather than invest the significant time and expense in changing the scope of the Company's business activities to encompasses the short term loans extended to Mylux, the directors are working towards securing an acquisition which will constitute a reverse and for which they will seek readmission of the Company to the Official List and to trading on the London Stock Exchange. Whilst there can be no certainty whether such a transaction can be achieved, nor when, the board believe that the volume of opportunities presented to them will ultimately result in a successful outcome and further announcements will be made in due course.